Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy

Manhal Izzy, Ghalib Jibara, Aws Aljanabi, Mustafa Alani, Emily Giannattasio, Hina Zaidi, Zaid Said, Paul Gaglio, Allan Wolkoff, John F. Reinus

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Background Individuals ineligible for interferon-based hepatitis C therapy may have a worse prognosis than patients who have failed or not received treatment. Aims To provide information about the limitations of medical treatment of hepatitis C in real-world patients. Methods We studied 969 treatment-ineligible patients and 403 treated patients enrolled between 1/1/01 and 6/30/06; data were collected until 3/31/13. Treatment barriers were grouped into five categories and classified as health-related or health-unrelated. Fibrosis stage was assessed initially and at the end of follow-up. Mortality was determined by search of the Social Security database. Death certificates of treatment-ineligible patients were reviewed. Results Initially, 288 individuals had advanced fibrosis and compensated disease; 87 untreated patients developed advanced fibrosis during follow-up. Health-related treatment barriers were more commonly associated with fibrosis progression and worse survival. During follow-up, 247 untreated patients died: 47% of liver-related and 53% of liver-unrelated causes. Patients with significant comorbid illness had the worst five- (70%) and ten-year (50.5%) survival. Despite high mortality (47%) in persons with decompensated liver disease, no treatment barrier was associated with a greater incidence of liver-related death. Only significant comorbid medical illness was an independent predictor of disease progression; however, it was not associated with a greater incidence of liver-related death. Furthermore, treated patients had better 10-year survival than untreated patients on Kaplan–Meier analysis (80.3% vs. 74.5%, P = 0.005). Conclusion Many patients with hepatitis C will die of non-liver-related causes and may not be helped by anti-viral treatment.

Original languageEnglish (US)
Pages (from-to)100-108
Number of pages9
JournalJournal of Clinical and Experimental Hepatology
Volume6
Issue number2
DOIs
StatePublished - Jun 1 2016

Keywords

  • hepatitis C
  • liver fibrosis
  • mortality
  • progression
  • treatment barrier

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy'. Together they form a unique fingerprint.

  • Cite this